[Clinical studies of cefotaxime in perinatal infection].
The therapeutic efficiency of a new cephalosporin derivative, cefotaxime, which is stable against beta-lactamase hydrolysis, has been studied in cases involving perinatal infection. The following results have been obtained. 1. In the treatment of 7 cases of infection, the preparation showed excellent efficacy in 1 case and good efficacy in 5 cases except 1 unknown case. 2. This drug has demonstrated its efficacy in the treatment of 5 cases of infections refractory to ABPC, out of which 1 had excellent and 3 had good results. 3. No side effects were observed in any of our patients. In conclusion, this drug shows excellent efficacy and high safety in the treatment of cases involving infection.
D000328:Adult; D002439:Cefotaxime / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004716:Endometritis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy*
D002439:Cefotaxime